Clinical applications of MALDI imaging technologies in cancer and neurodegenerative diseases

Uçal, Yasemin; Durer, Zeynep A. Oztug; Atak, Hakan; Kadioglu, Elif; Sahin, Betul; Coşkun, Abdurrahman; Baykal, Ahmet Tarık; Özpınar, Aysel

doi:10.1016/j.bbapap.2017.01.005

Cited by 51 publications

(49 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Matrix‐assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) is a powerful tool to visualize the spatial distribution of a wide range of biomolecules in tissue sections . MALDI MSI has been used as a complementary tool to histology, and applications include biomarker discovery, disease classification, tumor heterogeneity determination, and monitoring the distribution of drugs and metabolites in tissue to assess different stages of drug discovery and development . One of the major challenges of MALDI MSI for compound identification is the presence of many tissue components that can lead to ion suppression and obscure the analyte signal from low abundant molecules .…”

Section: Introductionmentioning

confidence: 99%

MALDI imaging directed laser ablation tissue microsampling for data independent acquisition proteomics

et al. 2019

View full text Add to dashboard Cite

A multimodal workflow for mass spectrometry imaging was developed that combines MALDI imaging with protein identification and quantification by liquid chromatography tandem mass spectrometry (LC-MS/MS). Thin tissue sections were analyzed by MALDI imaging, and the regions of interest (ROI) were identified using a smoothing and edge detection procedure. A midinfrared laser at 3-μm wavelength was used to remove the ROI from the brain tissue section after MALDI mass spectrometry imaging (MALDI MSI). The captured material was processed using a single-pot solidphase-enhanced sample preparation (SP3) method and analyzed by LC-MS/MS using ion mobility (IM) enhanced data independent acquisition (DIA) to identify and quantify proteins; more than 600 proteins were identified. Using a modified database that included isoform and the post-translational modifications chain, loss of the initial methionine, and acetylation, 14 MALDI MSI peaks were identified. Comparison of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of the identified proteins was achieved through an evolutionary relationships classification system.

show abstract

Section: Introductionmentioning

confidence: 99%

MALDI imaging directed laser ablation tissue microsampling for data independent acquisition proteomics

et al. 2019

View full text Add to dashboard Cite

show abstract

“…58,59 In any case, the two main kinds of MS investigations on AD brain tissues are: (i) MS proteomics studies aimed to identify and/or quantify Aβ peptides 60 as well as other proteins involved with the disease 61 ; (ii) MS imaging studies aimed to obtain Aβ peptides and/or fibril distribution in the various brain regions. [62][63][64][65] In the first group of studies, IP has been often applied in order to isolate the Aβ peptides and increase the sensitivity. 66 In this way, the main isoforms of Aβ in AD brains have been identified, and it was possible to discern between controls and AD patients by comparing specific areas of the brain, the hippocampus, and the cerebellum.…”

Section: Brainmentioning

confidence: 99%

“…In order to tackle this problem, special rapid autopsy programs, also known as “short post‐mortem interval autopsy,” have been developed . In any case, the two main kinds of MS investigations on AD brain tissues are: (i) MS proteomics studies aimed to identify and/or quantify Aβ peptides as well as other proteins involved with the disease; (ii) MS imaging studies aimed to obtain Aβ peptides and/or fibril distribution in the various brain regions . In the first group of studies, IP has been often applied in order to isolate the Aβ peptides and increase the sensitivity .…”

Section: Introductionmentioning

confidence: 99%

Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond

Grasso

2018

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Amyloid-β peptide (Aβ) accumulation and aggregation have been considered for many years the main cause of Alzheimer's disease (AD), and therefore have been the principal target of investigation as well as of the proposed therapeutic approaches (Grasso [2011] Mass Spectrom Rev. 30: 347-365). However, the amyloid cascade hypothesis, which considers Aβ accumulation the only causative agent of the disease, has proven to be incomplete if not wrong. In recent years, actors such as metal ions, oxidative stress, and other cofactors have been proposed as possible co-agents or, in some cases, main causative factors of AD. In this scenario, MS investigation has proven to be fundamental to design possible diagnostic strategies of this elusive disease, as well as to understand the biomolecular mechanisms involved, in the attempt to find a possible therapeutic solution. We review the current applications of MS in the search for possible Aβ biomarkers of AD to help the diagnosis of the disease. Recent examples of the important contributions that MS has given to prove or build theories on the molecular pathways involved with such terrible disease are also reviewed.

show abstract

“…It has also become evident that combine multiomics data are required to address the challenge of translational research. Mass spectrometry imaging (MSI) has emerged as a powerful tool for the direct detection of biomolecules, including proteins, peptides, glycans, metabolites, phospholipids, and glycolipids, in tissue samples (Buchberger, DeLaney, Johnson, & Li, ; Caprioli, ; Dreisewerd & Yew, ; Trim & Snel, ; Ucal et al, ). Several ionization sources are capable of ionizing the molecules on the surface of the sample and the mass spectrometer collects a mass spectrum at each pixel on the section with the resulting spatial resolution defined by the pixel size.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in mass spectrometry imaging for multiomics application in neurology

Gao

2018

J of Comparative Neurology

View full text Add to dashboard Cite

Mass spectrometry imaging (MSI) has emerged as a powerful tool for multiomics study in neurology. MSI combines the multichannel (m/z) measurement capability of mass spectrometers with a surface sampling process that allows for rapid probing and mapping of the characterized intact proteins, proteolytic digested peptides, released glycans, phospholipids, glycolipids, and small metabolites in brain tissues. The present review is focused on the application of MSI to the study of proteomics, glycomics, peptidomics, metabolomics, and lipidomics in mouse brain tissues. K E Y W O R D Smass spectrometry imaging, mouse brain,

show abstract

Clinical applications of MALDI imaging technologies in cancer and neurodegenerative diseases

Cited by 51 publications

References 221 publications

MALDI imaging directed laser ablation tissue microsampling for data independent acquisition proteomics

MALDI imaging directed laser ablation tissue microsampling for data independent acquisition proteomics

Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond

Recent advances in mass spectrometry imaging for multiomics application in neurology

Contact Info

Product

Resources

About